CN107759518A - 一种含三氟甲基吡啶的邻苯二甲酰胺衍生物及其应用 - Google Patents

一种含三氟甲基吡啶的邻苯二甲酰胺衍生物及其应用 Download PDF

Info

Publication number
CN107759518A
CN107759518A CN201711145742.3A CN201711145742A CN107759518A CN 107759518 A CN107759518 A CN 107759518A CN 201711145742 A CN201711145742 A CN 201711145742A CN 107759518 A CN107759518 A CN 107759518A
Authority
CN
China
Prior art keywords
nmr
chloro
pyridine
dmso
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201711145742.3A
Other languages
English (en)
Inventor
吴剑
徐方舟
王艳艳
余刚
薛伟
石军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou University
Original Assignee
Guizhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou University filed Critical Guizhou University
Publication of CN107759518A publication Critical patent/CN107759518A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

本发明公开了一种含三氟甲基吡啶的邻苯二甲酰胺衍生物,其特征在于:其结构通式如I所示:R1为卤素、C1‑C3烷氧基、C1‑C3烷硫基或C1‑C3烷基磺酰基;R2为单取代或双取代,且R2为H、甲基、氯、溴或氟;R3为C1‑C3烷基、环烷基、卤代烷基或羟基代烷基。

Description

一种含三氟甲基吡啶的邻苯二甲酰胺衍生物及其应用
技术领域
本发明涉及农用化学品领域,具体来讲,涉及一种含三氟甲基吡啶的邻苯二甲酰胺衍生物在制备杀虫剂中的应用。
背景技术
在绿色新农药的创制中,含氟农药是人们一直研究的热点领域。氟原子具有电子效应、类氢模拟效应、阻碍效应、脂溶性渗透效应的独特的性质,在药物化学、天然产物化学和农药化学及精细化学品等领域的应用越来越广泛(杨吉春,等.农药,2011,4,289-295)。据不完全统计近10年来所开发的农药新品种中含氟化合物高达50%以上,含氟农药已经成为现在农药行业开发与应用的主要方向(杨吉春,等.农药,2011,4,289-295),可见氟原子在农药中的重要地位。三氟甲基吡啶作为一类重要的含氟的杂环结构,也是当前商品化农药中的常见基团,在已登记的农药中,含三氟甲基吡啶结构的农药如氟啶虫胺腈、氟啶虫酰胺、啶虫丙醚、氟啶嘧磺隆、氟吡酰菌胺等近30个品种均含有三氟甲基吡啶结构。近些年来,含三氟甲基吡啶结构的化合物备受研究者的关注,研究者在其专利(如:WO2013191113,WO2014010737,WO2014021468,WO,2014119699,JP2015003906,WO2015072463,WO2016024587,CN104650038,WO2015177063,WO,2016023954等)中陆续公开了含三氟甲基吡啶结构的化合物具有优异的杀虫活性。
此外,邻苯二甲酰胺类杀虫剂也是近十年来人们创制杀虫剂的热点领域,近十年来,美国先正达公司、拜耳农科、贵州大学、南开大学等国内外很多研究机构先后申请了大量的专利,报道了大量具有良好杀虫活性的邻酰胺基苯甲酰胺类化合物。例如CN105315277、CN 102060846、CN102093341、WO2006040113、WO2010069502、WO2011157664、CN103420884等。
鉴于上述背景,为了获得高活性的新型化合物,并改善杀虫剂抗药性,扩宽杀虫谱的化合物。
发明内容
本发明要解决的技术问题是:在于将三氟甲基吡啶活性亚结构与邻苯二甲酰胺活性亚结构进行进行拼接,提供一种结构新颖的含三氟甲基吡啶的邻苯二甲酰胺衍生物,该化合物改善杀虫剂抗药性并扩宽杀虫谱。
本发明的技术方案是:一种含三氟甲基吡啶的邻苯二甲酰胺衍生物,其结构通式如I所示:R1为卤素、C1-C3烷氧基、C1-C3烷硫基或C1-C3烷基磺酰基;R2为单取代或双取代,且R2为H、甲基、氯、溴或氟;R3为C1-C3烷基、环烷基、卤代烷基或羟基代烷基。
所述的R2为双取代时,两个取代基相同或不同。
所述的R1为Cl、F、甲氧基、乙氧基、甲硫基、乙硫基、甲磺酰基或乙磺酰基;R2为H、3-甲基、5-氯、5-氯-3-甲基、3,5-二氯或3,5-二氟;R3为甲基,乙基,正丙基、异丙基、环丙基、2,2-二氟乙基、2,2,2-三氟乙基或羟基乙基。
所述的R1为Cl、乙氧基、乙硫基或乙磺酰基;R2为3-甲基、5-氯、5-氯-3-甲基、3,5-二氯或3,5-二氟;R3为甲基、乙基、正丙基、异丙基、环丙基、2,2-二氟乙基、2,2,2-三氟乙基或羟基乙基。
一种含三氟甲基吡啶的邻苯二甲酰胺衍生物的制备方法,包含以下步骤:
(1)在三口烧瓶中加入3-取代-5-(三氟甲基)吡啶甲酸,吡啶以及溶剂,冰盐浴条件下搅拌,然后用恒压滴液漏斗缓慢滴加甲磺酰氯,滴加完毕后加入取代邻氨基苯甲酸,反应5-10分钟后,继续滴加吡啶及甲磺酰氯,滴加完毕反应30-60分钟撤掉冰盐浴,12-24小时后停止反应,加入水及二氯甲烷萃取,收集有机相脱溶即得到2-(3-取代-5-(三氟甲基)吡啶-2-基)-取代-4H-苯并[d][1,3]恶嗪-4-酮;(2)在三口烧瓶中加入2-(3-取代-5-(三氟甲基)吡啶-2-基)-取代-4H-苯并[d][1,3]恶嗪-4-酮及溶剂,滴加取代胺,滴加完毕后继续常温搅拌6-8小时后停止反应,过滤、重结晶,即得到所述的化合物(I)。
所述的化合物在制备防治农作物害虫的农药或农药添加剂中的用途。
所述的化合物在制备防治小菜蛾、棉铃虫、蚜虫的农药或农药添加剂中的用途。
本发明的有益效果:本发明提供一种新型含有三氟甲基吡啶取代的邻苯二甲酰胺类化合物,生物活性测试结果表明,本发明提供的化合物的杀虫谱较宽,不仅对鳞翅目类害虫(如:小菜蛾、棉铃虫等)具有良好的防治效果,对同翅目类害虫(如蚜虫)也具有优良的防治效果。其相比于传统的邻苯二甲酰胺类杀虫剂,其杀虫谱有所拓宽(氯虫酰胺、氟苯虫酰胺等仅对鳞翅目害虫有效)。此外,由于氟原子具有电子效应、类氢模拟效应、脂溶性渗透效应等独特的性质,使得三氟甲基吡啶基团的引入可以增加化合物与靶标之间相互作用的几率,从而提高化合物的活性。
具体实施方式
本实施例中化合物(I-1~I-44)的合成方法均一致,所不同的是所采用的起始原料仅在有取代基上有所差别。以下通过部分典型的化合物的制备实例来具体地说明本发明的式I化合物的制备方法,这些实施例仅对本发明的制备方法进行说明,而不是对本发明的化合物进行限制。
实施例1:3-氯-N-(2,4-二氯-6-(环丙基氨基甲酰基)苯基)-5-(三氟甲基)吡啶酰胺(I-1)的制备:
(1)向25ml的三口烧瓶中加入0.5g(2.22mmol)的3-氯-5-(三氟甲基)吡啶甲酸,0.7g(8.87mmol)吡啶和5ml乙腈,冰盐浴降温到-5℃,随后用恒压滴液漏斗缓慢向体系滴加0.51g(4.43mmol)甲磺酰氯,滴加完毕后搅拌5min后,一次性向体系中加入0.5g(2.88mmol)2-氨基-3,5-二氯苯甲酸,搅拌10min后用恒压滴液漏斗缓慢滴加0.70g(8.87mmol)吡啶,滴加过程应该保持温度低于0℃,滴加完毕后继续搅拌15min,随后用恒压滴液漏斗继续缓慢滴加0.51g(4.43mmol)甲磺酰氯,滴加完毕后搅拌1h,撤去冰盐浴,反应温度慢慢升高到室温,反应12h后加入水及二氯甲烷萃取,取有机层过柱(石油醚:乙酸乙酯=10:1),得到中间体6,8-二氯-2-(3-氯-5-(三氟甲基)吡啶-2-基)-4H-苯并[d][1,3]噁嗪-4-酮。
(2)向25ml三口烧瓶中加入0.2g(0.51mmol)6,8-二氯-2-(3-氯-5-(三氟甲基)吡啶-2-基)-4H-苯并[d][1,3]噁嗪-4-酮以及4ml乙腈,室温搅拌,用恒压滴液漏斗滴加3ml环丙胺溶液,加毕,TLC跟踪反应,室温搅拌至反应完毕,旋干溶剂,柱层析(石油醚:乙酸乙酯=1:1),即可得3-氯-N-(2,4-二氯-6-(环丙基氨基甲酰基)苯基)-5-(三氟甲基)吡啶酰胺I-1,
实施例2:3-氯-N-(2,4-二氟-6-(甲酰胺基)苯基)-5-(三氟甲基)吡啶酰胺的制备(I-6):
(1)向25ml的三口烧瓶中加入2mmol)的3,5-二氟-5-(三氟甲基)吡啶甲酸,8.0mmol)吡啶和5ml乙腈,冰盐浴降温到-5℃,随后用恒压滴液漏斗缓慢向体系滴加0.51g(4.43mmol)甲磺酰氯,滴加完毕后搅拌10min后,一次性向体系中加入3mmol)2-氨基-3,5-二氟苯甲酸,搅拌10min后用恒压滴液漏斗缓慢滴加9mmol)吡啶,滴加过程应该保持温度低于0℃,滴加完毕后继续搅拌15min,随后用恒压滴液漏斗继续缓慢滴加4.5mmol甲磺酰氯,滴加完毕后搅拌1h,撤去冰盐浴,反应温度慢慢升高到室温,反应12h后加入水及二氯甲烷萃取,取有机层过柱(石油醚:乙酸乙酯=10:1),得到中间体6,8-二氟-2-(3-氯-5-(三氟甲基)吡啶-2-基)-4H-苯并[d][1,3]噁嗪-4-酮。
(2)向25ml三口烧瓶中加入0.2g(0.51mmol)6,8-二氟-2-(3-氯-5-(三氟甲基)吡啶-2-基)-4H-苯并[d][1,3]噁嗪-4-酮以及4ml乙腈,室温搅拌,用恒压滴液漏斗滴加2ml甲胺醇溶液,室温搅拌至反应完毕,旋干溶剂,重结晶,即得到产品I-6,收率97%,熔点178-179℃。
实施例3:3-氯-N-(2-((2,2-二氟乙基)甲酰基)-4,6-二氟苯基)-5-(三氟甲基)吡啶甲酰胺(I-18)的制备:
(1)向25ml的三口烧瓶中加入0.5g的3,5-二氟-5-(三氟甲基)吡啶甲酸,0.7g吡啶和5ml乙腈,冰盐浴降温到-5℃,随后用恒压滴液漏斗缓慢向体系滴加0.51g甲磺酰氯,滴加完毕后搅拌10min后,一次性向体系中加入0.5g2-氨基-3,5-二氟苯甲酸,搅拌10min后用恒压滴液漏斗缓慢滴加0.70g吡啶,滴加过程应该保持温度低于0℃,滴加完毕后继续搅拌15min,随后用恒压滴液漏斗继续缓慢滴加0.51g甲磺酰氯,滴加完毕后搅拌1h,撤去冰盐浴,反应温度慢慢升高到室温,反应12h后加入水及二氯甲烷萃取,取有机层过柱(石油醚:乙酸乙酯=10:1),得到中间体6,8-二氟-2-(3-氯-5-(三氟甲基)吡啶-2-基)-4H-苯并[d][1,3]噁嗪-4-酮。
(2)向25ml三口烧瓶中加入0.2g6,8-二氟-2-(3-氯-5-(三氟甲基)吡啶-2-基)-4H-苯并[d][1,3]噁嗪-4-酮以及4ml乙腈,室温搅拌,用恒压滴液漏斗滴加3ml二氟乙胺溶液,加毕,TLC跟踪反应,室温搅拌至反应完毕,旋干溶剂固体应乙醇重结晶,白色固体,收率88%,熔点170-172℃。
实施例4:3-氯-N-(4-氯-2-((2,2,2-三氟乙基)甲酰胺基)苯基)-5-(三氟甲基)吡啶甲酰胺(I-27)的制备:
(1)向25ml的三口烧瓶中加入0.5g的5-氯-5-(三氟甲基)吡啶甲酸,0.7g吡啶和5ml乙腈,冰盐浴降温到-5℃,随后用恒压滴液漏斗缓慢向体系滴加0.51g甲磺酰氯,滴加完毕后搅拌10min后,一次性向体系中加入0.5g)2-氨基-3,5-二氟苯甲酸,搅拌10min后用恒压滴液漏斗缓慢滴加0.70g吡啶,滴加过程应该保持温度低于0℃,滴加完毕后继续搅拌15min,随后用恒压滴液漏斗继续缓慢滴加0.51g甲磺酰氯,滴加完毕后搅拌1h,撤去冰盐浴,反应温度慢慢升高到室温,反应12h后加入水及二氯甲烷萃取,取有机层过柱(石油醚:乙酸乙酯=10:1),得到中间体6-氯-2-(3-氯-5-(三氟甲基)吡啶-2-基)-4H-苯并[d][1,3]噁嗪-4-酮。
(2)向25ml三口烧瓶中加入0.2g 6-氯-2-(3-氯-5-(三氟甲基)吡啶-2-基)-4H-苯并[d][1,3]噁嗪-4-酮以及4mL四氢呋喃,室温搅拌,用恒压滴液漏斗滴加3ml三氟乙胺盐酸盐溶液,加毕,TLC跟踪反应,室温搅拌至反应完毕,旋干溶剂固体应乙醇重结晶,白色固体,收率31.5%,熔点210-222℃。
实施例5:N-(4-氯-2-甲基-6-甲基甲酰胺基苯基)-3-乙硫基-5-三氟甲基-吡啶甲酰胺(I-35)的制备(I-35):
(1)向25ml的三口烧瓶中加入0.5g的5-乙硫基-5-(三氟甲基)吡啶甲酸,0.7g吡啶和5ml乙腈,冰盐浴降温到-5℃,随后用恒压滴液漏斗缓慢向体系滴加0.51g(4.43mmol)甲磺酰氯,滴加完毕后搅拌10min后,一次性向体系中加入0.5g 2-氨基-5-氯-3-甲基苯甲酸,搅拌10min后用恒压滴液漏斗缓慢滴加0.70g吡啶,滴加过程应该保持温度低于0℃,滴加完毕后继续搅拌15min,随后用恒压滴液漏斗继续缓慢滴加0.51g甲磺酰氯,滴加完毕后搅拌1h,撤去冰盐浴,反应温度慢慢升高到室温,反应12h后加入水及二氯甲烷萃取,取有机层过柱(石油醚:乙酸乙酯=10:1),得到中间体6-氯-2-(3-乙硫基-5-三氟甲基-吡啶-2-基)-8-甲基-4H-苯并[d][1,3]噁嗪-4-酮。
(2)向25ml三口烧瓶中加入0.2g 6-氯-2-(3-乙硫基-5-三氟甲基-吡啶-2-基)-8-甲基-4H-苯并[d][1,3]噁嗪-4-酮以及4mL乙醇,室温搅拌,用恒压滴液漏斗滴加3ml甲胺醇溶液,加毕,TLC跟踪反应,室温搅拌至反应完毕,旋干溶剂固体应乙醇重结晶即得到产品。
实施例6:N-(4-氯-2-甲基-6-甲基甲酰胺基苯基)-3-乙磺酰基-5-三氟甲基-吡啶甲酰胺(I-39)的制备:
(1)向50ml的三口烧瓶中加入1g(2.22mmol)的5-乙磺酰基-5-(三氟甲基)吡啶甲酸,0.7g(8.87mmol)吡啶和5ml乙腈,冰盐浴降温到-5℃,随后用恒压滴液漏斗缓慢向体系滴加0.51g(4.43mmol)甲磺酰氯,滴加完毕后搅拌10min后,一次性向体系中加入0.5g(2.88mmol)2-氨基-5-氯-3-甲基苯甲酸,搅拌10min后用恒压滴液漏斗缓慢滴加0.70g(8.87mmol)吡啶,滴加过程应该保持温度低于0℃,滴加完毕后继续搅拌15min,随后用恒压滴液漏斗继续缓慢滴加0.51g(4.43mmol)甲磺酰氯,滴加完毕后搅拌1h,撤去冰盐浴,反应温度慢慢升高到室温,反应12h后加入水及二氯甲烷萃取,取有机层过柱(石油醚:乙酸乙酯=10:1),得到中间体6-氯-2-(3-乙磺酰基-5-三氟甲基-吡啶-2-基)-8-甲基-4H-苯并[d][1,3]噁嗪-4-酮。
(2)向25ml三口烧瓶中加入0.2g(0.51mmol)6-氯-2-(3-乙磺酰基-5-三氟甲基-吡啶-2-基)-8-甲基-4H-苯并[d][1,3]噁嗪-4-酮以及4mL乙醇,室温搅拌,在加入滴加2三氟乙胺盐酸盐,室温搅拌至反应完毕,旋干溶剂固体应乙醇重结晶即得到产品。
实施例7:N-(4-氯-2-甲基-6-甲基甲酰胺基苯基)-3-乙磺酰基-5-三氟甲基-吡啶甲酰胺(I-42)的制备(I-42):
(1)向25ml的三口烧瓶中加入0.5g(2.22mmol)的5-乙磺酰基-5-(三氟甲基)吡啶甲酸,0.7g(8.87mmol)吡啶和5ml乙腈,冰盐浴降温到-5℃,随后用恒压滴液漏斗缓慢向体系滴加0.51g(4.43mmol)甲磺酰氯,滴加完毕后搅拌10min后,一次性向体系中加入0.5g(2.88mmol)2-氨基-5-氯-3-甲基苯甲酸,搅拌10min后用恒压滴液漏斗缓慢滴加0.70g(8.87mmol)吡啶,滴加过程应该保持温度低于0℃,滴加完毕后继续搅拌15min,随后用恒压滴液漏斗继续缓慢滴加0.51g(4.43mmol)甲磺酰氯,滴加完毕后搅拌1h,撤去冰盐浴,反应温度慢慢升高到室温,反应12h后加入水及二氯甲烷萃取,取有机层过柱(石油醚:乙酸乙酯=10:1),得到中间体6-氯-2-(3-乙磺酰基-5-三氟甲基-吡啶-2-基)-8-甲基-4H-苯并[d][1,3]噁嗪-4-酮。
(2)向25ml三口烧瓶中加入0.2g(0.51mmol)6-氯-2-(3-乙磺酰基-5-三氟甲基-吡啶-2-基)-8-甲基-4H-苯并[d][1,3]噁嗪-4-酮以及4mL乙醇,室温搅拌,滴加3ml乙胺醇溶液,加毕,TLC跟踪反应,室温搅拌至反应完毕,旋干溶剂固体应乙醇重结晶即得到产品。
采用上述类似的方法,可以制备得到本案中其他优选的化合物。所合成的部分化合物的核磁谱图数据、物化性质等列如下:
化合物I-1:3-氯-N-(2,4-二氯-6-环丙基甲酰胺基苯基)-5-三氟甲基吡啶甲酰胺,白色固体,收率79%,熔点191-192℃;1H NMR(500MHz,DMSO-D6)δ10.56(s,1H),9.05(s,1H),8.63(s,1H),8.44(d,J=3.7Hz,1H),7.84(d,J=2.2Hz,1H),7.49(d,J=2.2Hz,1H),2.69(td,J=7.2,3.7Hz,1H),0.64–0.57(m,2H),0.54–0.47(m,2H).19F NMR(471MHz,DMSO-D6)δ-60.74.13C NMR(126MHz,DMSO-D6)δ166.21,162.53,153.37,144.51,138.52,137.25,133.75,132.38,131.11,130.76,130.20,127.82(d,J=33.3Hz,127.56,123.01(q,J=273.4Hz),23.36,6.21.
化合物I-2:3-氯-N-(2-(环丙基甲酰氨基)-6-甲基苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率38%,熔点210-211℃;1H NMR(500MHz,DMSO-D6)δ10.40(s,1H),9.04(s,1H),8.63(s,1H),8.25(s,1H),7.32(d,J=49.2Hz,3H),2.73(s,1H),2.26(s,3H),0.61(s,2H),0.51(s,2H).19F NMR(471MHz,DMSO-D6)δ-60.73.13C NMR(126MHz,DMSO-D6)δ168.90,162.53,154.35,144.56,137.07,136.40,134.88,132.84,132.36,129.90,127.82(d,J=33.3Hz),127.14,126.30,123.06(d,J=273.0Hz),23.34,18.84,6.27.
化合物I-3:3-氯-N-(2-(环丙基甲酰胺基)-4,6-二氟苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率34%,熔点190-191℃;1H NMR(500MHz,DMSO-D6)δ10.49(s,1H),9.04(s,1H),8.63(s,1H),8.49(s,1H),7.51(t,J=8.3Hz,1H),7.22(d,J=7.8Hz,1H),2.73(d,J=3.5Hz,1H),0.63(d,J=5.5Hz,2H),0.53(s,2H).19F NMR(471MHz,DMSO-D6)δ-60.76,-111.24,-112.07.13C NMR(126MHz,DMSO-D6)δ166.24,162.57,160.29(dd,J=246.8,12.1Hz),157.80(dd,J=252.0,12.9Hz),153.37,144.55,137.24,136.81,130.19,128.04(q,J=33.6Hz),123.02(q,J=273.3Hz),119.39(d,J=12.6Hz),111.57(d,J=22.0Hz),106.52(t,J=25.7Hz),23.40,6.23.
化合物I-4:3-氯-N-(4-氯-2-(环丙基甲酰胺基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率23%,熔点223-224℃;1H NMR(500MHz,DMSO-D6)δ12.64(s,1H),9.10(s,1H),8.84(s,1H),8.70–8.54(m,2H),7.80(s,1H),7.62(d,J=7.7Hz,1H),2.83(s,1H),0.68(d,J=5.2Hz,2H),0.59(s,2H).19F NMR(471MHz,DMSO-D6)δ-60.81.13C NMR(126MHz,DMSO-D6)δ168.35,161.52,151.17,144.57,138.47,137.38,132.28,131.30,128.67,128.43,127.89,123.55,122.56,121.82,23.74,6.19.
化合物I-5:3-氯-N-(2,4-二氯-6-(甲酰胺基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率44%,熔点220-222℃;1H NMR(500MHz,DMSO-D6)δ10.59(s,1H),9.05(s,1H),8.62(s,1H),8.35(d,J=4.5Hz,1H),7.85(d,J=2.3Hz,1H),7.52(d,J=2.3Hz,1H),2.69(d,J=4.6Hz,3H).19F NMR(471MHz,DMSO-D6)δ-60.76.13C NMR(126MHz,DMSO-D6)δ165.56,162.65,153.59,144.58,138.56,137.16,133.87,132.42,131.23,130.81,130.08,127.98(q,J=33.4Hz),127.46,123.02(q,J=273.1Hz),26.71.
化合物I-6:3-氯-N-(2,4-二氟-6-(甲酰胺基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率97%,熔点178-179℃;1H NMR(500MHz,DMSO-D6)δ10.52(s,1H),9.05(s,1H),8.63(s,1H),8.43(d,J=4.3Hz,1H),7.52(dd,J=13.2,5.4Hz,1H),7.26(d,J=8.2Hz,1H),2.70(d,J=4.6Hz,3H).19F NMR(471MHz,DMSO-D6)δ-60.76,-111.23,-111.68.13C NMR(126MHz,DMSO-D6)δ165.58,162.56,160.30(dd,J=247.0,11.8Hz),157.83(dd,J=252.3,12.5Hz),153.36,144.57,137.25,136.61,130.18,128.02(q,J=33.5Hz),123.01(q,J=273.4Hz),119.58(d,J=14.6Hz),111.45(d,J=22.8Hz),106.60(t,J=25.8Hz),26.71.
化合物I-7:3-氯-N-(2-甲基-6-(甲酰胺基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率34%,熔点215-216℃;1H NMR(500MHz,DMSO-D6)δ10.48(s,1H),9.05(s,1H),8.62(s,1H),8.15(d,J=4.3Hz,1H),7.37(d,J=7.2Hz,1H),7.32(d,J=6.8Hz,1H),7.26(t,J=7.5Hz,1H),2.70(d,J=4.5Hz,3H),2.27(s,3H).19F NMR(471MHz,DMSO-D6)δ-60.76,-111.23,-111.68.
13C NMR(126MHz,DMSO-D6)δ168.22,162.61,154.47,144.64,137.02,136.44,134.71,133.01,132.44,129.80,127.77(q,J=33.3Hz),127.17,126.13,123.07(q,J=273.4Hz),26.67,18.89.
化合物I-8:3-氯-N-(4-氯-2-(甲酰胺基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率92%,熔点189-191℃。1H NMR(500MHz,DMSO-D6)δ12.73(s,1H),9.09(s,1H),8.88(s,1H),8.63(d,J=8.9Hz,2H),7.84(s,1H),7.62(d,J=8.6Hz,1H),2.75(d,J=3.9Hz,3H).19F NMR(471MHz,DMSO-D6)δ-60.84.13C NMR(126MHz,DMSO-D6)δ167.53,161.50,151.15,144.54,138.47,137.53,132.24,131.30,128.47,127.91,126.04(q,J=31.2Hz),123.54,122.90(q,J=273.7Hz),122.54,26.88.
化合物I-9:3-氯-N-(2-(乙酰氨基)-6-甲基苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率93%,熔点192-193℃。1H NMR(500MHz,DMSO-D6)δ10.43(s,1H),9.04(s,1H),8.62(s,1H),8.19(d,J=5.2Hz,1H),3.19(dt,J=14.1,7.1Hz,2H),2.26(s,3H),1.04(t,J=7.2Hz,3H).19F NMR(471MHz,DMSO-D6)δ-60.74.13C NMR(126MHz,DMSO-D6)δ167.50,162.55,154.30,144.58,137.07,136.42,134.94,132.93,132.37,129.86,127.82(q,J=33.1Hz),127.18,126.21,123.05(q,J=273.2Hz),34.47,18.87,15.06.
化合物I-10:3-氯-N-(2,4-二氯-6-(乙酰氨基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率61%,熔点210-211℃;1H NMR(500MHz,DMSO-D6)δ10.55(s,1H),9.04(s,1H),8.62(s,1H),8.38(s,1H),7.85(d,J=2.2Hz,1H),7.51(d,J=2.2Hz,1H),3.22–3.12(m,2H),1.04(t,J=7.2Hz,3H).19F NMR(471MHz,DMSO-D6)δ-60.77.13C NMR(126MHz,DMSO-D6)δ164.82,162.53,153.33,144.55,138.71,137.27,133.86,132.43,131.20,130.75,130.21,128.05(q,J=32.7Hz),127.52,123.01(q,J=273.0Hz),34.63,14.88.
化合物I-11:3-氯-N-(4-氯-2-(乙酰氨基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率85%,熔点198-199℃;1H NMR(500MHz,DMSO-D6)δ12.68(s,1H),9.08(s,1H),8.89(s,1H),8.67–8.58(m,2H),7.85(d,J=2.4Hz,1H),7.62(dd,J=9.0,2.3Hz,1H),3.28–3.22(m,2H),1.10(t,J=7.2Hz,3H).19F NMR(471MHz,DMSO-D6)δ-60.84.13C NMR(126MHz,DMSO-D6)δ166.85,161.50,151.17,144.55,138.47,137.51,132.20,131.29,128.54(q,J=33.5Hz),128.52,127.91,123.75,122.91(q,J=273.3Hz),122.55,34.79,14.83.
化合物I-12:3-氯-N-(2-(乙酰氨基)-4,6-二氟苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率96%,熔点170-171℃;1H NMR(500MHz,DMSO-D6)δ10.48(s,1H),9.04(s,1H),8.63(s,1H),8.46(s,1H),7.52(t,J=8.3Hz,1H),7.25(d,J=7.5Hz,1H),3.23–3.14(m,2H),1.06(t,J=7.2Hz,3H).19F NMR(471MHz,DMSO-D6)δ-60.76,-111.24,-111.87.13C NMR(126MHz,DMSO-D6)δ164.84,162.56,160.31(dd,J=246.8,11.8Hz),157.85(dd,J=252.4,12.7Hz),153.33,144.54,137.27,136.86(d,J=7.7Hz),130.19,128.03(d,J=33.4Hz),124.09,119.53(d,J=14.4Hz),123.01(d,J=273.2Hz),111.48(d,J=23.7Hz),106.52(t,J=25.8Hz),34.63,14.90.
化合物I-13:3-氯-N-(2,4-二氯-6-((2-羟乙基)氨基甲酰基)苯基)-5-(三氟甲基)吡啶甲酰胺,白色固体,收率6%,熔点157-158℃;1H NMR(500MHz,DMSO-D6)δ9.12(d,J=1.1Hz,1H),8.77(d,J=1.5Hz,1H),8.20(d,J=2.3Hz,1H),8.12(d,J=2.4Hz,1H),4.73(t,J=6.0Hz,1H),3.94(t,J=5.8Hz,2H),3.46(q,J=5.9Hz,2H).19F NMR(471MHz,DMSO-D6)δ-60.76.13C NMR(126MHz,DMSO-D6)δ160.03,153.71,152.31,145.03,142.55,137.23,135.15,133.11,132.68,131.49,127.90(q,J=33.3Hz),125.27,123.91,123.01(q,J=273.6Hz),58.22,47.75.化合物
I-14:3-氯-N-(2,4-二氟-6-((2-羟乙基)氨基甲酰基)苯基)-5-(三氟甲基)吡啶甲酰胺,白色固体,收率93%,熔点179-180℃;1H NMR(500MHz,DMSO-D6)δ10.51(s,1H),9.04(s,1H),8.64(s,1H),8.45(s,1H),7.53(s,1H),7.30(s,1H),4.66(s,1H),3.45(s,2H),3.23(s,2H).19F NMR(471MHz,DMSO-D6)δ-60.77,-111.30,-111.81.13C NMR(126MHz,DMSO-D6)δ165.25,162.50,160.29(dd,J=247.0,11.8Hz),157.80(dd,J=252.3,12.5Hz),153.16,144.53,137.32,136.62(d,J=8.0Hz),130.27,128.06(d,J=33.3Hz),123.01(q,J=273.2Hz),119.54(d,J=11.6Hz),111.66(d,J=22.6Hz),106.61(t,J=25.7Hz),60.01,42.65.
化合物I-15:3-氯-N-(2-((2-羟基乙基)氨基甲酰基)-6-甲基苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率65%,熔点185-186℃;1H NMR(500MHz,DMSO-D6)δ10.45(s,1H),9.04(d,J=0.9Hz,1H),8.62(d,J=1.3Hz,1H),8.14(t,J=5.6Hz,1H),7.36(dd,J=13.0,7.1Hz,2H),7.27(t,J=7.6Hz,1H),4.61(t,J=5.7Hz,1H),3.45(q,J=6.2Hz,2H),3.24(q,J=6.1Hz,2H),2.27(s,3H).19F NMR(471MHz,DMSO-D6)δ-60.75.13C NMR(126MHz,DMSO-D6)δ167.89,162.57,154.29,144.57,137.10,136.38,134.77,132.93,132.46,129.90,127.82(q,J=33.2Hz),127.16,126.33,123.05(d,J=273.4Hz),60.18,42.54,18.87.
化合物I-16:3-氯-N-(4-氯-2-((2-羟乙基)氨基甲酰基)苯基)-5-(三氟甲基)吡啶甲酰胺;白色固体,收率86%,熔点198-200℃;1H NMR(500MHz,DMSO-D6)δ12.63(s,1H),9.08(s,1H),8.87(s,1H),8.62(d,J=14.8Hz,2H),7.90(s,1H),7.63(d,J=8.8Hz,1H),3.53–3.45(m,2H).3.24(q,J=6.1Hz,2H).19F NMR(471MHz,DMSO-D6)δ-60.84.13C NMR(126MHz,DMSO-D6)δ167.26,161.48,151.12,144.55,138.50,137.46,132.20,131.31,128.73,128.55(d,J=33.5Hz),127.90,123.81,122.90(d,J=273.6Hz),122.51,59.82,42.81.
化合物I-17:3-氯-N-(2,4-二氯-6-((2,2-二氟乙基)氨基甲酰基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率77%,熔点204-205℃;1H NMR(500MHz,DMSO-D6)δ10.59(s,1H),9.05(s,1H),8.89(t,J=5.8Hz,1H),8.62(s,1H),7.90(d,J=2.1Hz,1H),7.53(d,J=2.2Hz,1H),6.03(tt,J=55.9,3.8Hz,1H),3.64–3.51(m,2H).13C NMR(126MHz,DMSO-D6)δ165.93,162.55,153.13,144.53(d,J=4.0Hz),137.48,137.31(d,J=3.6Hz),133.68,132.34,131.27,131.23,130.27,128.08(d,J=33.3Hz),127.68,123.00(q,J=272.9Hz),114.97(t,J=240.2Hz),42.05(t,J=26.5Hz).
化合物I-18:3-氯-N-(2-((2,2-二氟乙基)氨基甲酰基)-4,6-二氟苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率88%,熔点170-172℃;1H NMR(500MHz,DMSO-D6)δ10.50(s,1H),9.04(s,1H),8.91(d,J=5.5Hz,1H),8.63(s,1H),7.57(t,J=9.3Hz,1H),7.26(d,J=7.8Hz,1H),6.03(t,J=55.9Hz,1H),3.59(t,J=15.4Hz,2H).13C NMR(126MHz,DMSO-D6)δ165.88,162.63,160.26(dd,J=247.2,12.3Hz),157.83(dd,J=252.2,13.1Hz),153.22,144.53,137.30,135.97(d,J=7.8Hz),130.21,128.05(q,J=33.1Hz),123.01(q,J=273.6Hz),119.62(d,J=13.8Hz),114.94(t,J=240.2Hz),111.70(d,J=24.2Hz),106.99(t,J=25.7Hz),42.04(t,J=26.4Hz).
化合物I-19:3-氯-N-(2-((2,2-二氟乙基)氨基甲酰基)-6-甲基苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率52%,熔点205.6-206.4℃;1H NMR(500MHz,DMSO-D6)δ10.38(s,1H),9.05(s,1H),8.66(t,J=5.8Hz,1H),8.62(s,1H),7.41(d,J=7.1Hz,1H),7.34(d,J=7.5Hz,1H),7.29(t,J=7.5Hz,1H),6.05(tt,J=56.1,4.0Hz,1H),3.58(tt,J=15.3,4.8Hz,1H),2.28(s,2H).13C NMR(126MHz,DMSO-D6)δ168.51,162.63,154.34,144.58(d,J=3.9Hz),137.03(d,J=3.5Hz),136.46,134.17,132.98,132.80,129.87,127.80(q,J=33.2Hz),127.22,126.33,123.05(d,J=273.3Hz),115.09(t,J=240.2Hz),42.07(t,J=26.6Hz),18.72.
化合物I-20:3-氯-N-(4-氯-2-((2,2-二氟乙基)氨基甲酰基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率31%,熔点198-199℃;1H NMR(500MHz,DMSO-D6)δ12.44(d,J=5.9Hz,1H),9.25(s,1H)9.08(s,1H),8.67–8.51(m,2H),7.86(s,1H),7.66(dd,J=8.7,2.4Hz,1H),6.11(tt,J=55.7,3.7Hz,1H),3.81–3.51(m,2H).13C NMR(126MHz,DMSO-D6)δ167.84,161.47,150.88,144.51,138.53,137.46,132.68,131.40,128.75,128.59(q,J=33.3Hz),128.00,123.18,122.88(q,J=273.7Hz),122.81,114.85(t,J=240.2Hz),42.03(t,J=26.4Hz).
化合物I-21:3-氯-N-(2,4-二氯-6-(异丙基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率24%,熔点220-221℃;1H NMR(500MHz,DMSO-D6)δ10.54(s,1H),9.05(s,1H),8.62(s,1H),8.25(d,J=7.5Hz,1H),7.84(s,1H),7.48(s,1H),3.92(td,J=13.1,6.5Hz,1H),2.47(d,J=1.5Hz,2H).19F NMR(471MHz,DMSO-D6)δ-60.78.13C NMR(126MHz,DMSO-D6)δ164.10,162.42,153.04,144.50,138.89,137.38,133.82,132.44,131.11,130.66,130.31,128.11(q,J=33.4Hz),127.61,122.99(q,J=273.4Hz),41.67,22.59.
化合物I-22:3-氯-N-(2,4-二氟-6-(异丙基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率49%,熔点185-186℃;1H NMR(500MHz,DMSO-D6)δ10.48(s,1H),9.04(s,1H),8.62(s,1H),8.30(d,J=7.6Hz,1H),7.50(dd,J=13.1,5.4Hz,1H),7.23(d,J=7.1Hz,1H),3.96(dq,J=13.3,6.6Hz,1H),1.09(d,J=6.6Hz,6H).19F NMR(471MHz,DMSO-D6)δ-60.85,-111.24,-112.08,-112.11.13C NMR(126MHz,DMSO-D6)δ164.16,162.51,160.35(dd,J=247.1,11.9Hz),157.87(dd,J=252.3,12.4Hz),153.11,144.50,137.30,137.16(d,J=7.9Hz),130.27,128.10(q,J=33.4Hz),122.98(q,J=273.3Hz),119.38(d,J=14.4Hz),111.58(d,J=23.7Hz),106.41(t,J=25.8Hz),41.72,22.57.
化合物I-23:3-氯-N-(2-(异丙基)-6-甲基苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率49%,熔点185-186℃;1H NMR(500MHz,DMSO-D6)δ10.41(s,1H),9.04(d,J=0.8Hz,1H),8.61(d,J=1.0Hz,1H),8.05(d,J=7.7Hz,1H),7.36(d,J=7.4Hz,1H),7.31(d,J=6.4Hz,1H),7.26(t,J=7.5Hz,1H),3.97(dq,J=13.3,6.6Hz,1H),2.27(s,3H),1.08(d,J=6.6Hz,6H).19F NMR(471MHz,DMSO-D6)δ-60.80.13C NMR(126MHz,DMSO-D6)δ166.83,162.47,154.10,144.53(d,J=4.0Hz),137.14(d,J=3.5Hz),136.40,135.21,132.86,132.26,129.97,127.88(q,J=33.3Hz),127.15,126.37,123.03(q,J=273.3Hz),41.42,22.68,18.84.
化合物I-24:3-氯-N-(4-氯-2-(异丙基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率72%,熔点239-240℃;1H NMR(500MHz,DMSO-D6)δ12.62(s,1H),9.08(s,1H),8.75–8.54(m,3H),7.85(s,1H),7.62(d,J=8.1Hz,1H),4.05(dd,J=12.9,6.4Hz,1H),1.13(d,J=6.3Hz,7H).19F NMR(471MHz,DMSO-D6)δ-60.84.13C NMR(126MHz,DMSO-D6)δ166.17,161.48,151.17,144.55,138.47,137.40,132.11,131.29,128.62,128.41,127.90,124.05,122.54,121.82,41.86,22.54.
化合物I-25:3-氯-N-(2,4-二氯-6-((2,2,2-三氟乙基)氨基甲酰基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率48%,熔点222-223℃;1H NMR(500MHz,DMSO-D6)δ10.57(s,1H),9.13(s,1H),9.05(s,1H),8.62(s,1H),7.92(s,1H),7.51(s,1H),3.99(s,3H).19FNMR(471MHz,DMSO-D6)δ-60.81,-70.30.13C NMR(126MHz,DMSO-D6)δ165.81,162.45,158.53,152.80,144.47,139.78,137.35,133.99,132.48,131.45,130.42,128.12(q,J=33.3Hz),127.69,125.08(q,J=279.5Hz),122.99(q,J=273.4Hz),120.00.
化合物I-26:3-氯-N-(2,4-二氟-6-(((2,2,2-三氟乙基)-2-氮杂)羰基)苯基)-5-(三氟甲基)吡啶甲酰胺,白色固体,收率72.4%,熔点171-172℃;1H NMR(500MHz,DMSO-D6)δ10.47(s,1H),9.17(s,1H),9.03(s,1H),8.62(s,1H),7.59(t,J=8.0Hz,1H),7.25(d,J=7.4Hz,1H),4.25–3.81(m,2H).19F NMR(471MHz,DMSO-D6)δ-60.84,-70.30,-110.75,-112.27.13C NMR(126MHz,DMSO-D6)δ165.82,162.62,160.36(dd,J=247.5,12.4Hz),158.00(dd,J=251.9,12.7Hz),153.00,144.45,137.29,135.84(d,J=8.1Hz),130.32,128.09(q,J=33.2Hz),125.08(q,J=279.3Hz),122.99(d,J=273.3Hz),121.90,119.72(d,J=16.1Hz),111.77(d,J=23.0Hz),107.21(t,J=25.7Hz).
化合物I-27:3-氯-N-(4-氯-2-((2,2,2-三氟乙基)氨基甲酰基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率31.5%,熔点210-222℃;1H NMR(500MHz,DMSO-D6)δ12.33(s,1H),9.49(t,J=6.0Hz,1H),9.06(d,J=0.5Hz,1H),8.63–8.58(m,2H),7.87(d,J=2.4Hz,1H),7.68(dd,J=9.0,2.4Hz,1H),4.13–4.02(m,2H).19F NMR(471MHz,DMSO-D6)δ-60.90,-70.15.13C NMR(126MHz,DMSO-D6)δ167.91,161.44,150.77,144.42,138.54,137.47,132.93,131.46,129.03,128.79,128.37(d,J=33.3Hz),128.46,128.07,125.12(q,J=279.5Hz),122.96.122.87(q,J=273.7Hz)
化合物I-28:33-氯-N-(4-氯-2-(环丙基氨基)-6-甲基苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率69.9%,熔点246-247℃;1H NMR(500MHz,DMSO-D6)δ10.41(s,1H),9.04(s,1H),8.62(s,1H),8.37(d,J=3.8Hz,1H),7.48(d,J=1.7Hz,1H),7.31(d,J=2.0Hz,1H),2.71(td,J=7.0,3.6Hz,1H),2.26(s,3H),0.61(q,J=6.6Hz,2H),0.52(d,J=3.0Hz,2H).19F NMR(471MHz,DMSO-D6)δ-60.74.13C NMR(126MHz,DMSO-D6)δ167.43,162.62,154.17,144.54,139.03,137.05,136.57,131.99,131.70,131.27,129.91,127.86(q,J=33.0Hz),125.94,123.04(q,J=273.2Hz),23.35,18.59,6.22.
化合物I-29:3-氯-N-(4-氯-2-甲基-6-(甲基氨基甲酰基)苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率51.7%,熔点238-239℃;1H NMR(500MHz,DMSO-D6)δ10.47(s,1H),9.05(s,1H),8.62(s,1H),8.28(d,J=4.0Hz,1H),7.50(s,1H),7.36(s,1H),2.69(d,J=4.3Hz,3H),2.26(s,3H).19F NMR(471MHz,DMSO-D6)δ-60.76.13C NMR(126MHz,DMSO-D6)δ166.76,162.70,154.26,144.63,139.09,137.02,136.48,132.13,131.76,131.31,129.83,127.84(q,J=33.2Hz),125.84,123.05(q,J=273.0Hz),26.68,18.63.
化合物I-30:3-氯-N-(4-氯-2-(乙基氨基甲酰基)-6-甲基苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率69.2%,熔点227-228℃;1H NMR(500MHz,DMSO-D6)δ10.44(s,1H),9.04(s,1H),8.62(s,1H),8.33(s,1H),7.50(s,1H),7.35(s,1H),3.18(s,3H),2.27(s,3H),1.05(s,3H).19F NMR(471MHz,DMSO-D6)δ-60.72.13C NMR(126MHz,DMSO-D6)δ166.03,162.63,154.14,144.61,139.08,137.07,136.68,132.09,131.70,131.31,129.88,127.86(q,J=32.3Hz).,125.89,123.04(q,J=273.8Hz.,34.55,18.62,14.96.
化合物I-31:3-氯-N-(4-氯-2-((2-羟基乙基)氨基甲酰基)-6-甲基苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率9.9%,熔点200-201℃;1H NMR(500MHz,DMSO-D6)δ9.10(d,J=1.0Hz,1H),8.76(d,J=1.4Hz,1H),7.99(d,J=2.5Hz,1H),7.83–7.78(m,1H),4.71(t,J=5.9Hz,1H),3.95(t,J=6.0Hz,2H),3.45(q,J=6.0Hz,2H),2.45(s,3H).19F NMR(471MHz,DMSO-D6)δ-60.74.13C NMR(126MHz,DMSO-D6)δ167.89,162.57,154.28,144.55,137.08,136.38,134.77,132.92,132.46,129.90,127.82(q,J=33.2Hz),127.16,126.33,123.05(d,J=273.4Hz),60.18,42.54,18.87.
化合物I-32:3-氯-N-(4-氯-2-((2,2-二氟乙基)氨基甲酰基)-6-甲基苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率27.1%,熔点229-230℃;1H NMR(500MHz,DMSO-D6)δ10.41(s,1H),9.04(s,1H),8.81(s,1H),8.62(s,1H),7.54(s,1H),7.37(s,1H),6.04(t,J=55.7Hz,1H),3.57(s,2H),2.28(s,3H).19F NMR(471MHz,DMSO-D6)δ-60.76,-120.96,-121.08.13C NMR(126MHz,DMSO-D6)δ167.07,162.70,154.12,144.61,139.09,137.07,135.76,132.15,131.28,129.89,127.86(q,J=33.1Hz),127.47,126.03,123.04(q,J=273.3Hz),115.05(t,J=240.1Hz),42.07(t,J=26.7Hz),18.49.
化合物I-33:3-氯-N-(4-氯-2-(异丙基)-6-甲基苯基)-5-(三氟甲基)吡啶酰胺,白色固体,收率76.0%,熔点220-221℃;1H NMR(500MHz,DMSO-D6)δ10.41(s,1H),9.03(d,J=0.8Hz,1H),8.61(d,J=1.3Hz,1H),8.19(d,J=7.7Hz,1H),7.48(d,J=2.3Hz,1H),7.32(d,J=2.4Hz,1H),3.93(dt,J=13.3,6.7Hz,1H),2.26(s,3H),1.07(d,J=6.7Hz,6H).19FNMR(471MHz,DMSO-D6)δ-60.77.13C NMR(126MHz,DMSO-D6)δ165.34,162.57,153.97,144.54,139.05,137.12,136.90,132.02,131.60,131.31,129.94,127.90(q,J=33.3Hz),125.98,123.02(q,J=273.4Hz),41.54,22.64,18.60.
化合物I-34:N-(4-氯-2-((2,2,2-三氟乙基)氨基甲酰基)苯基)-3-(甲硫基)-5-(三氟甲基)吡啶酰胺,白色固体,收率72.0%;1H NMR(500MHz,DMSO-D6)δ9.28(s,1H),8.40(dd,J=9.0,6.0Hz,1H),8.06(dd,J=22.0,2.9Hz,1H),7.68(dd,J=15.0,2.9Hz,1H),6.49(s,1H),4.03(q,J=18.0Hz,1H),3.83(q,J=18.0Hz,1H),2.46(s,2H);13C NMR(125MHz,DMSO-D6)δ169.36,163.94,154.84,149.89,142.97,139.82,135.02(q,J=31.5Hz)133.03,132.58,132.07,131.27,125.79,125.08(q,J=268.1Hz),124.92(q,J=268.1Hz),124.85,43.20,16.55.
化合物I-35:N-(4-氯-2-甲基-6-((2,2,2-三氟乙基)氨基甲酰基)苯基)-3-(乙硫基)-5-(三氟甲基)吡啶酰胺,白色固体,收率68%;1H NMR(500MHz,DMSO-D6)δ8.70(s,1H),8.41(d,J=3.1Hz,1H),8.08(d,J=2.9Hz,1H),7.94(d,J=2.9Hz,1H),7.69(d,J=2.9Hz,1H),6.27(s,1H),3.99(q,J=17.9Hz,1H),3.79(q,J=18.0Hz,1H),3.00(q,J=13.2Hz,2H),2.13(s,3H),1.31(t,J=13.2Hz,3H);13C NMR(125MHz,DMSO-D6)δ169.66,163.41,155.81,148.44,142.48(q,J=3.7Hz),142.19,137.57,137.25(q,J=3.7Hz),135.64(q,J=31.5Hz),135.19,134.07,133.08,131.13,128.36,125.08(q,J=268.1Hz),124.92(q,J=268.1Hz),42.35(q,J=31.5Hz).,43.20,24.92,18.95,13.02.
化合物I-36:N-(4-氯-2-(环丙基氨基)-6-甲基苯基)-3-(乙硫基)-5-(三氟甲基)吡啶酰胺,白色固体,收率68%;1H NMR(500MHz,Chloroform)δ8.41(d,J=2.9Hz,1H),7.94(d,J=2.9Hz,1H),7.69(d,J=2.9Hz,1H),5.94(s,1H),3.96(s,1H),3.83(d,J=3.1Hz,1H),3.00(q,J=13.2Hz,2H),2.75(p,J=17.8Hz,1H),2.13(s,3H),1.31(t,J=13.2Hz,3H),0.99–0.74(m,2H),0.67–0.20(m,2H);13C NMR(125MHz,Common NMR Solvents)δ167.31,163.41,155.81,148.44,142.48,141.83,137.64,137.25,135.19,134.68,133.66,131.02,128.80,124.92,25.09,24.92,18.95,13.02,10.65.
化合物I-37:N-(4-氯-2-((2,2-二氟乙基)氨基甲酰基)-6-甲基苯基)-3-(乙硫基)-5-(三氟甲基)吡啶酰胺,收率78%;1H NMR(500MHz,Chloroform)δ8.85(s,1H),8.41(s,1H),8.11(s,1H),7.94(s,1H),7.69(s,1H),6.90(tt,J=114.5,9.3Hz,1H),6.10(s,1H),3.62(td,J=41.8,9.4Hz,2H),3.00(q,J=13.2Hz,2H),2.13(s,3H),1.31(t,J=13.2Hz,3H);13C NMR(125MHz,Common NMR Solvents)δ169.37,163.41,155.81,148.44,142.48(q,J=3.7Hz),142.19,137.57,137.25(q,J=3.7Hz),135.58,135.32,135.06,134.81,134.07,133.08,131.13,128.36,128.13,124.92(q,J=268.1Hz),41.94(t,J=26.7Hz)24.92,18.95,13.02.
化合物I-38:N-(4-氯-2-甲基-6-((2,2,2-三氟乙基)氨基甲酰基)苯基)-3-(乙硫基)-5-(三氟甲基)吡啶酰胺,收率68%;1H NMR(500MHz,Chloroform)δ8.41(d,J=2.9Hz,1H),8.04(d,J=2.9Hz,1H),7.94(d,J=2.9Hz,1H),7.69(d,J=2.9Hz,1H),6.48(s,1H),3.98(q,J=17.9Hz,1H),3.83(q,J=17.9Hz,1H),3.00(q,J=13.2Hz,2H),2.13(s,3H),1.31(t,J=13.2Hz,3H);
13C NMR(125MHz,Common NMR Solvents)δ169.66,163.41,155.81,148.44,δ142.48(q,J=3.7Hz),142.19,137.57,137.25(q,J=3.7Hz),135.19(q,J=32.4Hz)134.07,133.08,131.13,128.36,125.08,125.00(q,J=268.1Hz),124.92,43.19(q,J=26.7Hz),24.92,18.95,13.02.
化合物I-39:N-(4-氯-2-甲基-6-((2,2,2-三氟乙基)氨基甲酰基)苯基)-3-(乙基磺酰基)-5-(三氟甲基)吡啶酰胺,收率73%;1H NMR(500MHz,Chloroform)δ9.03(d,J=2.9Hz,1H),8.59(s,1H),8.38(d,J=2.9Hz,1H),7.93(d,J=3.1Hz,1H),7.68(d,J=2.9Hz,1H),7.67(s,1H),3.89(dq,J=21.6,18.0Hz,2H),3.51(q,J=13.6Hz,2H),2.13(s,3H),1.19(t,J=13.6Hz,3H);13C NMR(125MHz,Common NMR Solvents)δ169.66,162.81,152.08,151.46,145.27,142.19,137.57,137.01,134.07,133.08,132.50(q,J=32.4Hz),131.13,128.36,125.08(d,J=268.1Hz),124.92,122.77(q,J=268.1Hz)52.69,43.19(q,J=26.7Hz),18.95,7.67.
化合物I-40:N-(4-氯-2-((2,2-二氟乙基)氨基甲酰基)-6-甲基苯基)-3-(乙基磺酰基)-5-(三氟甲基)吡啶酰胺,收率73%;1H NMR(500MHz,Chloroform)δ9.04(s,1H),8.47(s,1H),7.94(s,1H),7.69(s,1H),6.53(tt,J=114.7,9.5Hz,1H),6.35(s,1H),3.72–3.45(m,4H),2.13(s,3H),1.19(t,J=13.6Hz,3H);13C NMR(125MHz,Common NMR Solvents)δ169.37,162.81,152.08,151.46(q,J=3.7Hz),145.27,142.19,137.57,137.01(q,J=3.7Hz),134.07,133.08,132.50(q,J=32.4Hz),131.13,128.36,124.92(q,J=268.1Hz),52.69,41.94,41.94(t,J=26.7Hz),18.95,7.67.
化合物I-41:N-(4-氯-2-(环丙基氨基)-6-甲基苯基)-3-(乙基磺酰基)-5-(三氟甲基)吡啶酰胺,收率68%;1H NMR(500MHz,Chloroform)δ9.04(d,J=2.9Hz,1H),8.61(d,J=3.1Hz,1H),7.94(d,J=2.9Hz,1H),7.69(d,J=2.9Hz,1H),7.57(s,1H),7.15(s,1H),3.51(q,J=13.6Hz,2H),2.75(p,J=17.8Hz,1H),2.13(s,3H),1.19(t,J=13.6Hz,3H),0.90–0.49(m,4H);13C NMR(125MHz,Common NMR Solvents)δ167.31,162.81,152.08,151.46,145.27,141.83,137.64,137.01,134.68,133.66,132.50(q,J=32.4Hz),131.02,128.80,124.92(q,J=268.1Hz),52.69,25.09,18.95,10.65,7.67.
化合物I-42:N-(4-氯-2-甲基-6-(甲基氨基甲酰基)苯基)-3-(乙基磺酰基)-5-(三氟甲基)吡啶酰胺,收率75%;1H NMR(500MHz,Chloroform)δ9.04(d,J=3.1Hz,1H),8.69(s,1H),8.51(d,J=3.1Hz,1H),7.94(d,J=2.9Hz,1H),7.69(d,J=2.9Hz,1H),5.85(s,1H),3.51(q,J=13.6Hz,2H),2.81(s,3H),2.13(s,3H),1.19(t,J=13.6Hz,3H);13C NMR(125MHz,CommonNMR Solvents)δ169.87,162.81,152.08,151.46,145.27,142.57,137.57,137.01,133.47,132.57,132.50(q,J=32.4Hz),131.35,128.00,124.92(q,J=268.1Hz),52.69,26.37,18.95,7.67.
实施例8:对小菜蛾的杀虫活性
采用国际抗性行动委员会(IRAC)提出的浸叶法(J.Agric.Food Chem.,2007,55(23):9614–9619.)。用配制好的待测药液。用直头眼科镊子浸渍甘蓝叶片,时间3-5秒,甩掉余液。每次1片,每个样品共3片。按样品标记顺序依次放在处理纸上。待药液干后,放入具有标记的10cm长的直型管内,接入2龄小菜蛾幼虫30头,用纱布盖好管口。将试验处理置于标准处理室内,96h检查结果以拨针轻触虫体,不动者为死亡。计算死亡率(实验做3次重复,取平均值)。以商品药毒死蜱为对照药剂。
计算死亡率和校正死亡率:
式中:P1—死亡率;K—死亡虫数;N—处理总虫数。
式中:P2—校正死亡率;Pt—处理死亡率;P0—空白对照死亡率。若对照死亡率<5%,无需校正;对照死亡率在5-20%之间,应按公式(2)进行校正;对照死亡率>20%,试验需重做。
部分化合物的活性结果如表2。
表2部分化合物对小菜蛾的杀虫活性
从表2中可以看出,所合成的部分化合物I-1,I-2,I-3,I-5,I-7,I-10,I-12,I-16,I-21,I-27,I-28,I-29,I-30,I-33,I-35,I-40,I-41,和I-42对小菜蛾的杀虫活性显示了优异的活性。上述的化合物在制备防治小菜蛾的农药或农药添加剂中的用途。
实施例9:对棉铃虫的杀虫活性测试
采用饲料混药法,从配置好的溶液中移取3mL加入到27g的刚配置好的饲料中,得到稀释十倍的所需浓度。药剂混匀后均匀地倒入干净的24孔板中,晾凉后接入24头棉铃虫,观察3-4天后检查结果。死亡率的计算方法与实施例6相同。
部分化合物的活性结果如表3
表3部分化合物对棉铃虫的杀虫活性
从表3中可以看出,所合成的部分化合物I-2,I-10,I-21,I-28,I-29,I-30,I-33,I-38,I-41和I-42对棉铃虫的杀虫活性显示了优异的活性。上述的化合物在制备防治棉铃虫的农药或农药添加剂中的用途。
对蚜虫的杀虫活性测试
采用浸渍法,将有60头左右蚜虫(混合种群)的蚕豆叶片在药液中充分浸润10s后,置于湿润棉花上,自然晾干后置于观察室内饲养和观察。72h后检查结果。以0.1%吐温水为空白对照。死亡率的计算方法与实施例6的公式相同。
表4部分化合物在500mg/L浓度下对蚜虫的杀虫活性初筛结果/%
化合物编号 活性/% 化合物编号 活性/%
I-1 54.2 I-18 45.3
I-2 83.3 I-19 76.7
I-3 79.2 I-20 88.7
I-4 58.3 I-21 86.5
I-5 70.8 I-22 88.5
I-6 45.8 I-31 45.3
I-7 70.8 I-33 76.7
I-8 41.7 I-35 76.7
I-9 58.3 I-36 88.7
I-10 91.7 I-38 45.3
I-11 88.7 I-39 50.2
I-12 70.6 I-40 90.0
I-15 98.2 I-41 100
I-16 73.5 I-42 90.5
I-17 55.7 氯虫酰胺 0
测试了部分化合物在500mg/L浓度下对蚕豆蚜的杀虫活性,结果见表4所示。从表中可以看出,部分化合物对蚜虫表现出了较好的杀虫活性,其中如化合物I-2、I-10、I-11、I-15、I-20、I-36、I-40、I-41、I-42对蚜虫的活性均大于80%,上述化合物在制备防治蚜虫的农药或农药添加剂中的用途。

Claims (5)

1.一种含三氟甲基吡啶的邻苯二甲酰胺衍生物,其特征在于:其结构通式如I所示:R1为卤素、C1-C3烷氧基、C1-C3烷硫基或C1-C3烷基磺酰基;R2为单取代或双取代,且R2为H、甲基、氯、溴或氟;R3为C1-C3烷基、环烷基、卤代烷基或羟基代烷基。
2.根据权利要求1所述的一种含三氟甲基吡啶的邻苯二甲酰胺衍生物,其特征在于:所述的R2为双取代时,两个取代基相同或不同。
3.根据权利要求1所述的一种含三氟甲基吡啶的邻苯二甲酰胺衍生物,其特征在于:R1为Cl、F、甲氧基、乙氧基、甲硫基、乙硫基、甲磺酰基或乙磺酰基;R2为H、3-甲基、5-氯、5-氯-3-甲基、3,5-二氯或3,5-二氟;R3为甲基,乙基,正丙基、异丙基、环丙基、2,2-二氟乙基、2,2,2-三氟乙基或羟基乙基。
4.根据权利要求1所述的一种含三氟甲基吡啶的邻苯二甲酰胺衍生物,其特征在于:R1为Cl、乙氧基、乙硫基或乙磺酰基;R2为3-甲基、5-氯、5-氯-3-甲基、3,5-二氯或3,5-二氟;R3为甲基、乙基、正丙基、异丙基、环丙基、2,2-二氟乙基、2,2,2-三氟乙基或羟基乙基。
5.根据权利要求1-4之一所述的一种含三氟甲基吡啶的邻苯二甲酰胺衍生物的制备方法,其特征在于:包含以下步骤:(1)在三口烧瓶中加入3-取代-5-(三氟甲基)吡啶甲酸,吡啶以及溶剂,冰盐浴条件下搅拌,然后用恒压滴液漏斗缓慢滴加甲磺酰氯,滴加完毕后加入取代邻氨基苯甲酸,反应5-10分钟后,继续滴加吡啶及甲磺酰氯,滴加完毕反应30-60分钟撤掉冰盐浴,12-24小时后停止反应,加入水及二氯甲烷萃取,收集有机相脱溶即得到2-(3-取代-5-(三氟甲基)吡啶-2-基)-取代-4H-苯并[d][1,3]恶嗪-4-酮;(2)在三口烧瓶中加入2-(3-取代-5-(三氟甲基)吡啶-2-基)-取代-4H-苯并[d][1,3]恶嗪-4-酮及溶剂,滴加取代胺,滴加完毕后继续常温搅拌6-8小时后停止反应,过滤、重结晶,即得到所述的化合物(I)。
CN201711145742.3A 2017-07-27 2017-11-17 一种含三氟甲基吡啶的邻苯二甲酰胺衍生物及其应用 Pending CN107759518A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710624019 2017-07-27
CN2017106240197 2017-07-27

Publications (1)

Publication Number Publication Date
CN107759518A true CN107759518A (zh) 2018-03-06

Family

ID=61278322

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711145742.3A Pending CN107759518A (zh) 2017-07-27 2017-11-17 一种含三氟甲基吡啶的邻苯二甲酰胺衍生物及其应用

Country Status (1)

Country Link
CN (1) CN107759518A (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110452234A (zh) * 2019-08-29 2019-11-15 贵州大学 一种含三氟甲基吡啶二甲酰胺的席夫碱的衍生物及其应用
CN110526863A (zh) * 2019-08-29 2019-12-03 贵州大学 一种三氟甲基吡啶的酰基硫脲和酰基脲类衍生物及其应用
CN110606828A (zh) * 2019-07-23 2019-12-24 贵州大学 一种含手性硫醚结构的三氟甲基吡啶酰胺衍生物及其应用
CN110606840A (zh) * 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1419537A (zh) * 2000-03-22 2003-05-21 纳幕尔杜邦公司 杀虫的邻氨基苯甲酰胺
CN101941917A (zh) * 2009-07-06 2011-01-12 中国中化股份有限公司 一种酰胺类化合物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1419537A (zh) * 2000-03-22 2003-05-21 纳幕尔杜邦公司 杀虫的邻氨基苯甲酰胺
CN101941917A (zh) * 2009-07-06 2011-01-12 中国中化股份有限公司 一种酰胺类化合物及其用途

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110606840A (zh) * 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
CN110606828A (zh) * 2019-07-23 2019-12-24 贵州大学 一种含手性硫醚结构的三氟甲基吡啶酰胺衍生物及其应用
CN110452234A (zh) * 2019-08-29 2019-11-15 贵州大学 一种含三氟甲基吡啶二甲酰胺的席夫碱的衍生物及其应用
CN110526863A (zh) * 2019-08-29 2019-12-03 贵州大学 一种三氟甲基吡啶的酰基硫脲和酰基脲类衍生物及其应用
CN110526863B (zh) * 2019-08-29 2022-05-03 贵州大学 一种含三氟甲基吡啶的酰基硫脲或酰基脲类衍生物及其应用

Similar Documents

Publication Publication Date Title
CN107759518A (zh) 一种含三氟甲基吡啶的邻苯二甲酰胺衍生物及其应用
ES2370534T3 (es) Agente para el control de plagas que contiene un derivado de piridil-metanamina novedoso o una de sus sales.
JP5911725B2 (ja) 新規ハロゲン置換化合物
JP5296688B2 (ja) 殺虫化合物
EP1717237B1 (en) Anthranilamides, process for the production thereof, and pest controllers containing the same
CN101659655A (zh) 一类吡唑酰胺衍生物及其应用
BRPI0713612A2 (pt) composto, método de combate e controle de insetos, acarinos, nematóides ou moluscos, e, composição inseticida, acaricida, nematicida ou moluscicida
BRPI0707722A2 (pt) compostos, processo para a preparaÇço de compostos, composiÇço agrÍcola, uso de compostos, mÉtodos para combater fungos fitopatogÊnicos, para combater pestes artràpedes, para proteger culturas de ataque ou infestaÇço por pestes artràpedes, para proteger sementes da infestaÇço por pestes artràpedes e das raÍzes e rebentos de mudas da infestaÇço por pestes artràpodes, e para proteger materiais nço-vivos do ataque ou infestaÇço por pestes artràpedes, e, semente
TW201427961A (zh) 四唑啉酮化合物及其用途
CN104447688B (zh) 一种吡唑酰胺类化合物及其应用
TW201100013A (en) Insecticidal compounds
EP2253617A1 (de) Halogen-substituierte Verbindungen als Pestizide
TW200526605A (en) Substituted arylpyrazoles
CN102827145B (zh) 一种新型氘代邻氨基苯甲酰胺化合物及其制备方法和应用
CN110526863A (zh) 一种三氟甲基吡啶的酰基硫脲和酰基脲类衍生物及其应用
BRPI0710751A2 (pt) composto, mÉtodo de combater e controlar insetos, acarinos, nematàdeos ou moluscos, e, composiÇço inseticida, acaridica ou nematicida
CN108218848A (zh) 一种三氟甲基吡啶联噁二唑(醚)类衍生物及其应用
CN105601632B (zh) 含嘌呤结构的卤苯氰基吡唑类化合物及制备方法和应用
CN110372531B (zh) 含α-羰基酰胺结构的醚类乙酰胺衍生物及其应用
CN105153037B (zh) 一种唑虫酰脲化合物
CN105820167B (zh) 一种具有杀虫作用的芳基吡唑嘌呤类化合物、制备方法及应用
CN105121433B (zh) 抗病毒化合物、其药学上可接受的盐或光学异构体、用于制备它们的方法以及包含它们作为有效成分的用于预防或治疗病毒性疾病的药物组合物
CN106928196A (zh) 一种吡唑甲酰胺基苯甲酰胺及其制备方法和用途
CN109232534B (zh) 含杂环二芳胺基吡唑甲酰胺类化合物及其制备方法与应用
JP2012532172A (ja) 殺虫性化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180306

RJ01 Rejection of invention patent application after publication